Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis‐causing pathogens
Microbial Biotechnology · 2023-12 · 16 (12) · 2367-2386
DOI: 10.1111/1751-7915.14339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 18.10.2023. Verfasst von Niels Vander Elst und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gene Technology, Department of Biosystems, Faculty of Bioscience Engineering, KU Leuven, Heverlee, Belgium. Hauptthemen laut MEDLINE: Mastitis, Bovine, Streptococcal Infections. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Research Foundation of Flanders (FWO Vlaanderen) as Hercules project.
Abstract (Originalsprache)
Bacteriophage‐derived endolysins are a novel class of antimicrobials known to rapidly kill bacteria, including antibiotic‐resistant strains. We here engineered endolysins against the bovine mastitis pathogens Streptococcus uberis , Streptococcus agalactiae and Streptococcus dysgalactiae , also targeting intracellular survival and biofilm formation. For this purpose, high‐throughput DNA assembly was used to create a library with >80,000 theoretical endolysin variants for screening of their bacteriolytic activity against Gram‐positive isolates from (sub)clinically affected cows. This lytic activity was evaluated by turbidity reduction and time‐kill assays in phosphate‐buffered saline and pasteurized whole cow's milk to allow a rank up of the most potent leading candidates. A top candidate was selected with a 4.0 log killing efficacy against S. uberis , also showing similar activity against S. agalactiae and S. dysgalactiae . This top candidate eradicated S. uberis biofilm and showed intracellular activity in two bovine mammary epithelial cell lines as was confirmed by confocal microscopy. A potentiating effect on cloxacillin, a beta‐lactam penicillin used to intramammarily treat bovine Gram‐positive mastitis, was observed for this top candidate endolysin in raw cow's milk from (sub)clinically infected udders. Our in vitro results indicate that engineered endolysins may have a future role as add‐on in the treatment of bovine streptococcal mastitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Gene Technology, Department of Biosystems, Faculty of Bioscience Engineering, KU Leuven, Heverlee, Belgium.
- Laboratory of Biochemistry, Department of Veterinary and Biosciences, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
- Laboratory of Applied Biotechnology, Department of Biotechnology, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.
- Laboratory of Immunology, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
ORCID-Profile: Niels Vander Elst, Joni Bert, Herman Favoreel, Rob Lavigne, Evelyne Meyer, Yves Briers
Förderung
- Fonds Wetenschappelijk Onderzoek
- Research Foundation of Flanders (FWO Vlaanderen) as Hercules project
Zitieren
APA
Vander Elst, N., Bert, J., Favoreel, H., Lavigne, R., Meyer, E., & Briers, Y. (2023). Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis‐causing pathogens. Microbial Biotechnology, 16(12), 2367-2386. https://doi.org/10.1111/1751-7915.14339
Vancouver
Vander Elst N, Bert J, Favoreel H, Lavigne R, Meyer E, Briers Y. Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis‐causing pathogens. Microbial Biotechnology. 2023;16(12):2367-2386. doi:10.1111/1751-7915.14339
BibTeX
@article{VanderElst2023,
author = {Vander Elst, Niels and Bert, Joni and Favoreel, Herman and Lavigne, Rob and Meyer, Evelyne and Briers, Yves},
title = {Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis‐causing pathogens},
journal = {Microbial Biotechnology},
year = {2023},
volume = {16},
number = {12},
pages = {2367--2386},
doi = {10.1111/1751-7915.14339}
}
EUVIMED